Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: When transitioning to new analytical platforms, laboratories must assess the analytical performances of their methods. This study aimed to verify the precision and trueness of the Maglumi X8 device for thyroid-stimulating hormone (TSH) and free thyroxine (FT4) tests and to compare its performance with that of the Advia Centaur XP system previously used in our laboratory.
Methods: Precision and trueness verifications for TSH and FT4 were performed using three levels of Bio-Rad Quality Control (QC) materials following the CLSI EP15-A3 guidelines. Each day consisted of one run with five replicates, resulting in 25 analyses performed using three levels of QC material over five days. Passing-Bablok regression and Bland-Altman analyses were performed for method comparison analysis, following the CLSI EP09c guidelines.
Results: The repeatability coefficients of variation (CVs) of TSH for levels 1, 2, and 3 were 2.170, 1.945, and 2.567%, respectively, whereas the within-laboratory (WL) CVs were 2.720, 2.786, and 2.609%, respectively. The repeatability CVs of FT4 for levels 1, 2, and 3 were 3.262, 1.326, and 0.696%, respectively, whereas the WL CVs were 4.848, 4.309, and 4.879%, respectively. The bias or overall mean values obtained in the study for TSH and FT4 levels were within the verification targets. TSH levels were found to be lower on Maglumi X8 [1.770 (1.190 to 2.790)] than Centaur XP [1.975 (1.185 to 3.315)]. FT4 levels were found to be higher on Maglumi X8 [1.305 (1.200 to 1.450)] than Centaur XP [1.210 (1.090 to 1.460)]. The bias between the two methods obtained from the Bland-Altman analysis for TSH and FT4 was -3.76% and 6.68%, respectively. Although the calculated bias for TSH fell within the desirable targets based on biological variation, FT4 did not meet these targets.
Conclusions: The precision and trueness verification results for TSH and FT4 demonstrated acceptable performance under the CLSI EP15-A3. TSH results between the two analyzers were consistent and can be transferred; FT4 results from Maglumi X8 require careful interpretation and may need harmonization and standardization due to the observed bias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2024.241017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between subclinical hypothyroidism and vitamin D deficiency: Insights from a case-control study.
Medicine (Baltimore)
September 2025
Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Subclinical hypothyroidism (SCH) is biochemically characterized by elevated thyrotropin (thyroid-stimulating hormone [TSH]) levels, while free thyroxine (FT4) levels remain normal. Given the high prevalence of vitamin D deficiency in Iran, investigating the association between vitamin D levels and SCH may improve treatment. A case-control study was conducted at the endocrinology clinic of Imam Khomeini Hospital, affiliated with Ahvaz Jundishapur University of Medical Sciences.
View Article and Find Full Text PDFCase Report: A homozygous selenocysteine insertion sequence-binding protein 2 () gene mutation in a pediatric patient.
Front Pediatr
August 2025
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Selenocysteine insertion sequence-binding protein 2 () is crucial for the biosynthesis of selenoproteins, including iodothyronine deiodinases, which play a vital role in thyroid hormone metabolism. Mutations in can disrupt thyroid function, leading to various clinical manifestations across multiple systems. We present the case of a 3-year-old Saudi female who was referred for genetic testing due to poor growth, developmental abnormalities, and notable facial dysmorphism.
View Article and Find Full Text PDFTrimester-Specific Reference Range for Thyroid Function Tests (TFTs) in Normal Pregnant Women at a Tertiary Care Centre.
Indian J Endocrinol Metab
August 2025
Department of Gynaecology and Obstetrics, MKCG Medical College, Berhampur, Odisha, India.
Introduction: Gestational age, ethnicity, assay method, thyroid autoimmunity and iodine status of the community affect thyroid hormone levels in pregnancy, and there is a need to establish trimester-specific reference ranges for thyroid hormones across different regions of the world. There was no previous study regarding this from this part of the country. The aim of this study was to establish trimester-specific reference range for thyroid hormones during pregnancy in a tertiary care centre in Southern Odisha.
View Article and Find Full Text PDFRisk factors and timing of postoperative hypothyroidism onset following hemithyroidectomy.
Auris Nasus Larynx
September 2025
Department of Otolaryngology, Tenri Hospital, Tenri, Nara, Japan.
Objective: This study aimed to identify prognostic factors for postoperative hypothyroidism and assess the timing of its onset in patients who underwent hemithyroidectomy for thyroid tumors. Despite normal preoperative thyroid function, some patients develop postoperative hypothyroidism, necessitating lifelong thyroid hormone replacement therapy. Identifying risk factors and establishing appropriate follow-up guidelines are essential for optimizing patient management.
View Article and Find Full Text PDFDiagnostic value of thyroid-related serological indicators and pan-immune-inflammation value for differentiated thyroid carcinoma.
Front Immunol
September 2025
School of Medicine, Tarim University, Alaer, China.
Background: Over the past decade, the remarkable rise in differentiated thyroid carcinoma (DTC) incidence, combined with the limitations of conventional diagnostic approaches, have prompted this study to explore the diagnostic value of thyroid-related serological indicators and pan-immune-inflammation value (PIV) for DTC, based on advancements in molecular biology and immunology.
Methods: Based on postoperative pathological diagnosis, the present retrospective research comprised 112 individuals afflicted with DTC (observation group) and 93 individuals having benign thyroid tumors (control group) from January 2023 to January 2025. Differences in clinical data between the two groups were analyzed via univariate statistical methods.